174 search results for: Pathophysiology
Gap in Care Leads to Progression of Fibrosis in EoE
Dr. Evan Dellon discusses the clinical implications of gaps in medical care on the risk of fibrotic progression in EoE.
Importance of Assessing Multiple Disease Domains in EoE
Prof. Arjan Bredenoord and Dr. Evan Dellon emphasize the need to assess multiple disease domains to get the complete picture of patients’ EoE.
Impact of Delayed EoE Diagnosis on Disease Progression and QoL
Join Prof. Arjan Bredenoord as he discusses the importance of early diagnosis of EoE.
KOL Video Interview – Dr. Eric Simpson
In this exclusive KOL interview, Dr. Eric Simpson explores the cumulative, long-term impact of atopic dermatitis and highlights the potential benefits of initiating treatment early to help manage disease burden.
Identifying BP: How do symptoms of BP and their severity alter patient diagnosis?
Dr. Victoria Werth explains how diagnosing BP can pose many difficulties in patients due to the variation of symptoms and symptom severity. Dr. Werth also discusses what burden and challenges BP patients might expect as a result.
EoE Quest: Navigating the Patient Experience
Want to test your EoE knowledge while learning more about the patient journey? Try EoE Quest, an engaging and educational interactive experience.
How FeNO Measurement Can Improve Severe Asthma Management — Presented in Spanish by Dr. Miguel Lanz
Join Dr. Miguel Lanz as he explains, in Spanish, the clinical utility of FeNO as a biomarker in severe asthma.
Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Enno Schmidt highlights the role of type 2 cytokines involved in the dysregulated Type 2 immune responses that contribute to inflammation and subsequent itch in bullous pemphigoid.
Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson outlines why early, targeted control of type 2 inflammation may modify the course of atopic dermatitis by addressing upstream drivers of barrier dysfunction, dysbiosis, and itch.
Which Biomarkers of AD Might Be Robust Enough to Be Evaluated as a Measure of Disease Modification?
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares reviews the cellular and molecular pathways underlying atopic dermatitis and considers which biomarkers may one day serve as robust measures of disease modification, despite no validated options currently being available.
The Risks of Associated Systemic and Atopic Comorbidities with AD
Dr. Paller explores the multifaceted impact of AD, highlighting its association with various comorbidities such as food allergies, asthma, allergic rhinitis, and mental health disorders.
Factors Associated With Development of Atopic Comorbidities in AD
Dr. Paller discusses factors influencing AD chronicity and comorbidities, focusing on disease severity, early onset, heredity, multiple allergies, and urban living as important in evaluating AD’s lasting effects on children.
